Frontiers in Immunology (Sep 2022)
Serial infection with SARS-CoV-2 Omicron BA.1 and BA.2 following three-dose COVID-19 vaccination
- Hope R. Lapointe,
- Francis Mwimanzi,
- Peter K. Cheung,
- Peter K. Cheung,
- Yurou Sang,
- Fatima Yaseen,
- Rebecca Kalikawe,
- Sneha Datwani,
- Rachel Waterworth,
- Gisele Umviligihozo,
- Siobhan Ennis,
- Landon Young,
- Winnie Dong,
- Don Kirkby,
- Laura Burns,
- Victor Leung,
- Victor Leung,
- Victor Leung,
- Daniel T. Holmes,
- Daniel T. Holmes,
- Mari L. DeMarco,
- Mari L. DeMarco,
- Janet Simons,
- Janet Simons,
- Nancy Matic,
- Nancy Matic,
- Nancy Matic,
- Julio S.G. Montaner,
- Julio S.G. Montaner,
- Chanson J. Brumme,
- Chanson J. Brumme,
- Natalie Prystajecky,
- Natalie Prystajecky,
- Masahiro Niikura,
- Christopher F. Lowe,
- Christopher F. Lowe,
- Christopher F. Lowe,
- Marc G. Romney,
- Marc G. Romney,
- Marc G. Romney,
- Mark A. Brockman,
- Mark A. Brockman,
- Mark A. Brockman,
- Zabrina L. Brumme,
- Zabrina L. Brumme
Affiliations
- Hope R. Lapointe
- British Columbia Centre for Excellence in HIV/AIDS, Vancouver, BC, Canada
- Francis Mwimanzi
- Faculty of Health Sciences, Simon Fraser University, Burnaby, BC, Canada
- Peter K. Cheung
- British Columbia Centre for Excellence in HIV/AIDS, Vancouver, BC, Canada
- Peter K. Cheung
- Faculty of Health Sciences, Simon Fraser University, Burnaby, BC, Canada
- Yurou Sang
- Faculty of Health Sciences, Simon Fraser University, Burnaby, BC, Canada
- Fatima Yaseen
- Department of Molecular Biology and Biochemistry, Simon Fraser University, Burnaby, BC, Canada
- Rebecca Kalikawe
- Faculty of Health Sciences, Simon Fraser University, Burnaby, BC, Canada
- Sneha Datwani
- Faculty of Health Sciences, Simon Fraser University, Burnaby, BC, Canada
- Rachel Waterworth
- Faculty of Health Sciences, Simon Fraser University, Burnaby, BC, Canada
- Gisele Umviligihozo
- Faculty of Health Sciences, Simon Fraser University, Burnaby, BC, Canada
- Siobhan Ennis
- Faculty of Health Sciences, Simon Fraser University, Burnaby, BC, Canada
- Landon Young
- Division of Medical Microbiology and Virology, St. Paul’s Hospital, Vancouver, BC, Canada
- Winnie Dong
- British Columbia Centre for Excellence in HIV/AIDS, Vancouver, BC, Canada
- Don Kirkby
- British Columbia Centre for Excellence in HIV/AIDS, Vancouver, BC, Canada
- Laura Burns
- Department of Pathology and Laboratory Medicine, Providence Health Care, Vancouver, BC, Canada
- Victor Leung
- Division of Medical Microbiology and Virology, St. Paul’s Hospital, Vancouver, BC, Canada
- Victor Leung
- Department of Pathology and Laboratory Medicine, Providence Health Care, Vancouver, BC, Canada
- Victor Leung
- Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada
- Daniel T. Holmes
- Department of Pathology and Laboratory Medicine, Providence Health Care, Vancouver, BC, Canada
- Daniel T. Holmes
- Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada
- Mari L. DeMarco
- Department of Pathology and Laboratory Medicine, Providence Health Care, Vancouver, BC, Canada
- Mari L. DeMarco
- Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada
- Janet Simons
- Department of Pathology and Laboratory Medicine, Providence Health Care, Vancouver, BC, Canada
- Janet Simons
- Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada
- Nancy Matic
- Division of Medical Microbiology and Virology, St. Paul’s Hospital, Vancouver, BC, Canada
- Nancy Matic
- Department of Pathology and Laboratory Medicine, Providence Health Care, Vancouver, BC, Canada
- Nancy Matic
- Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada
- Julio S.G. Montaner
- British Columbia Centre for Excellence in HIV/AIDS, Vancouver, BC, Canada
- Julio S.G. Montaner
- Department of Medicine, University of British Columbia, Vancouver, BC, Canada
- Chanson J. Brumme
- British Columbia Centre for Excellence in HIV/AIDS, Vancouver, BC, Canada
- Chanson J. Brumme
- Department of Medicine, University of British Columbia, Vancouver, BC, Canada
- Natalie Prystajecky
- Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada
- Natalie Prystajecky
- British Columbia Centre for Disease Control Public Health Laboratory, Vancouver, BC, Canada
- Masahiro Niikura
- Faculty of Health Sciences, Simon Fraser University, Burnaby, BC, Canada
- Christopher F. Lowe
- Division of Medical Microbiology and Virology, St. Paul’s Hospital, Vancouver, BC, Canada
- Christopher F. Lowe
- Department of Pathology and Laboratory Medicine, Providence Health Care, Vancouver, BC, Canada
- Christopher F. Lowe
- Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada
- Marc G. Romney
- Division of Medical Microbiology and Virology, St. Paul’s Hospital, Vancouver, BC, Canada
- Marc G. Romney
- Department of Pathology and Laboratory Medicine, Providence Health Care, Vancouver, BC, Canada
- Marc G. Romney
- Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada
- Mark A. Brockman
- British Columbia Centre for Excellence in HIV/AIDS, Vancouver, BC, Canada
- Mark A. Brockman
- Faculty of Health Sciences, Simon Fraser University, Burnaby, BC, Canada
- Mark A. Brockman
- Department of Molecular Biology and Biochemistry, Simon Fraser University, Burnaby, BC, Canada
- Zabrina L. Brumme
- British Columbia Centre for Excellence in HIV/AIDS, Vancouver, BC, Canada
- Zabrina L. Brumme
- Faculty of Health Sciences, Simon Fraser University, Burnaby, BC, Canada
- DOI
- https://doi.org/10.3389/fimmu.2022.947021
- Journal volume & issue
-
Vol. 13
Abstract
SARS-CoV-2 Omicron infections are common among individuals who are vaccinated or have recovered from prior variant infection, but few reports have immunologically assessed serial Omicron infections. We characterized SARS-CoV-2 humoral responses in an individual who acquired laboratory-confirmed Omicron BA.1.15 ten weeks after a third dose of BNT162b2, and BA.2 thirteen weeks later. Responses were compared to 124 COVID-19-naive vaccinees. One month post-second and -third vaccine doses, the participant’s wild-type and BA.1-specific IgG, ACE2-displacement and virus neutralization activities were average for a COVID-19-naive triple-vaccinated individual. BA.1 infection boosted the participant’s responses to the cohort ≥95th percentile, but even this strong “hybrid” immunity failed to protect against BA.2. Reinfection increased BA.1 and BA.2-specific responses only modestly. Though vaccines clearly protect against severe disease, results highlight the continued importance of maintaining additional protective measures to counteract the immune-evasive Omicron variant, particularly as vaccine-induced immune responses naturally decline over time.
Keywords
